A
Alemtuzumab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Post-marketing information
Dear Healthcare Professional Letters
Subsidy Information and Financing Scheme
No
Active ingredient: Alemtuzumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
04/01/2022 Disease-modifying therapies for treating multiple sclerosis
The Ministry of Health’s Drug Advisory Committee has recommended:
Fingolimod 0.25 mg and 0.5 mg capsules for treating adults and children with relapsing-remitting multiple sclerosis, and
Siponimod 0.25 mg and 2 mg tablets for treating adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity.
Subsidy status
[R] Fingolimod 0.25 mg and 0.5 mg capsules and siponimod 0.25 mg and 2 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications.
[NR] MAF assistance does not apply to any formulations or strengths of alemtuzumab, cladribine, dimethyl fumarate, interferon beta-1a, natalizumab, ofatumumab or teriflunomide for treating adults or children with any form of multiple sclerosis.